Ryan J. Li

Ryan J. Li

Auto-generated profile, based on publicly available information

Ryan J. Li

Oregon Health & Science University, Portland, Oregon

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 November 2020 in Cancers
Verified
Journal Article
Open access
PDF file
ZCZigui Chen
Zigui Chen
PWPo Yee Wong
Po Yee Wong
CNCherrie W. K. Ng
Cherrie W. K. Ng
LLLinlin Lan
Linlin Lan
SFSherwood Fung
Sherwood Fung
Jason Y. K. ChanJason Y. K. Chan
Jason Y. K. Chan
The role of oral microbiota in head and neck squamous cell carcinoma (HNSCC) is poorly understood. Here we sought to evaluate the association of the bacterial microbiome with host gene methylation and patient outcomes, and to explore its potential as a biomarker for early detection or intervention. Here we performed 16S rRNA gene amplicon sequencing in sixty-eight HNSCC patients across both tissue and oral rinse samples to identify oral bacteria with differential abundance between HNSCC and controls. A subset of thirty-one pairs of HNSCC tumor tissues and the adjacent normal tissues were characterized for host gene methylation profile using bisulfite capture sequencing. We observed significant enrichments of Fusobacterium and Peptostreptococcus in HNSCC tumor tissues when compared to the adjacent normal tissues, and in HNSCC oral rinses when compared to healthy subjects, while ten other bacterial genera were largely depleted. These HNSCC-related bacteria were discriminative for HNSCC and controls with area under the receiver operating curves (AUCs) of 0.84 and 0.86 in tissue and oral rinse samples, respectively. Moreover, Fusobacterium nucleatum abundance in HNSCC cases was strongly associated with non-smokers, lower tumor stage, lower rate of recurrence, and improved disease-specific survival. An integrative analysis identified that enrichment of F. nucleatum was associated with host gene promoter methylation, including hypermethylation of tumor suppressor genes LXN and SMARCA2, for which gene expressions were downregulated in the HNSCC cohort from The Cancer Genome Atlas. In conclusion, we identified a taxonomically defined microbial consortium associated with HNSCC that may have clinical potential regarding biomarkers for early detection or intervention. Host–microbe interactions between F. nucleatum enrichment and clinical outcomes or host gene methylation imply a potential role of F. nucleatum as a pro-inflammatory driver in initiating HNSCC without traditional risk factors, which warrants further investigation for the underlying mechanisms.

9 June 2022 in JAMA Otolaryngology–Head & Neck Surgery
Verified
Journal Article
Open access
PDF file
VPVivek C. Pandrangi
Vivek C. Pandrangi
SSSuparna N. Shah
Suparna N. Shah
JBJennifer D. Bruening
Jennifer D. Bruening
MWMark K. Wax
Mark K. Wax
DCDaniel Clayburgh
Daniel Clayburgh
RLRyan J. Li
Ryan J. Li
Importance: Optimal postoperative pain management is challenging. Virtual reality (VR) provides immersive, 3-dimensional experiences that may improve pain control and reduce reliance on pharmacologic pain management.Objective: To evaluate use of VR on postoperative pain management after head and neck surgery.Design, Setting, and Participants: This prospective, pilot randomized clinical trial was conducted at Oregon Health & Science University from July 2020 to October 2021 and included patients hospitalized after major head and neck surgery.Interventions: Similar 15-minute interactive gaming experiences (Angry Birds) using an Oculus Quest VR headset (VR intervention) or a handheld smartphone device (control).Main Outcomes and Measures: The primary outcome was postintervention pain reduction. Pain scores were obtained preintervention, immediately after intervention, and then hourly for 4 hours. Secondary outcomes included changes in opioid use, measured as milligram morphine equivalents (MMEs), and patient experiences with their intervention using 5-point Likert scales.Results: Of the 30 patients randomized for inclusion, the final population included 14 patients in the VR cohort and 15 patients in the control cohort; the majority of patients were male (26 of 29 [90%]), and the mean (SD) age was 58.3 (13.8) years. After outlier removal, there were clinically meaningful reductions in postintervention pain among patients in the VR group immediately after intervention (mean difference, −1.42; 95% CI, −2.15 to −0.70; d = 1.50), at 1 hour (mean difference, −0.86; 95% CI, −1.90 to 0.14; d = 0.67), 2 hours (mean difference, −1.07; 95% CI, −2.30 to 0.14; d = 0.69), and 3 hours (mean difference, −1.36; 95% CI, −2.80 to 0.13; d = 0.71) compared with patients in the control group. Patients in the VR group also demonstrated reductions in 4-hour postintervention opioid use compared with 4-hour preintervention opioid use (mean difference, −9.10 MME; 95% CI, −15.00 to −1.27 MME; d = 0.90) and 8-hour postintervention opioid use compared with 8-hour preintervention opioid use (mean difference, −14.00 MME; 95% CI, −25.60 to −2.40 MME; d = 0.94). There were no meaningful differences in subjective patient experiences with their respective interventions.Conclusions and Relevance: In this randomized clinical trial, VR reduced pain scores and opioid use compared with a control intervention. Virtual reality may be a useful adjunct for postoperative pain management after head and neck surgery.Trial Registration: ClinicalTrials.gov Identifier: NCT04464304

14 March 2019 in Current Treatment Options in Oncology
Verified
Journal Article
Closed access
PDF file
DKDavid Kim
David Kim
RLRyan Li
Ryan Li

1 November 2018 in JAMA Otolaryngology–Head & Neck Surgery
Verified
Journal Article
Open access
PDF file
RLRyan J. Li
Ryan J. Li
MLMyriam Loyo Li
Myriam Loyo Li
ELEnrique Leon
Enrique Leon
CNCherrie W. K. Ng
Cherrie W. K. Ng
MSMaisie Shindo
Maisie Shindo
Jason Y. K. ChanJason Y. K. Chan
Jason Y. K. Chan
The worsening opioid epidemic in the United States has led to a staggering number of overdose-related deaths. The Centers for Disease Control and Prevention estimates that more than 350 000 people have died of opioid overdose from 1999 to 2016. In 2016 alone, 40% of the 46 000 opioid-related deaths were related to opioid prescriptions.1 This in part resulted from a substantial change in prescribing patterns for opioids, with a 4-fold increase from 1999 to 2014. This period marked a surge in choices of available opioids and a public call from major regulatory and governmental bodies to consider pain as the “fifth vital sign.”2,3 The death rate related to opioid overdose is higher than that for motor vehicle accidents and higher than AIDS-related death rates during the height of the human immunodeficiency virus epidemic.4,5 As surgeons, we must increasingly engage in solutions for the current opioid epidemic given our unique, potential position to bridge health care, policy, and industry in this trial.6 We are also the second largest subgroup of physicians involved in opioid prescribing.7

28 March 2022 in Cancer Biology & Therapy
Verified
Journal Article
Open access
MVMyles Vigoda
Myles Vigoda
CMChase Mathieson
Chase Mathieson
NENathaniel Evans
Nathaniel Evans
CHCarolyn Hale
Carolyn Hale
JJJennifer Jennings
Jennifer Jennings
MKMolly Kulesz-Martin
Molly Kulesz-Martin
In this study, we report a differential response of mitogen-activated protein kinase–kinase (MEK) inhibitor trametinib in 20 head and neck squamous cell carcinoma (HNSCC) patients’ tumor-derived cell cultures. Relatively sensitive and resistant cases to trametinib were identified using high throughput metabolic assays and validated in extended dose response studies in vitro. High throughput metabolic assays exploring combination therapies with trametinib were subjected to synergy models and maximal synergistic dose analyses. These yielded several candidates, including axtinib, GDC-0032, GSK-690693, and SGX-523. The combination regimen of trametinib and AXL/MET/VEGFR inhibitor glesatinib showed initial efficacy both in vitro and in vivo (92% reduction in tumor volume). Sensitivity was validated in vivo in a patient-derived xenograft (PDX) model in which trametinib as a single agent effected reduction in tumor volume up to 72%. Reverse Phase Protein Arrays (RPPA) demonstrated differentially expressed proteins and phosphoproteins upon trametinib treatment. Furthermore, resistant cell lines showed a compensatory mechanism via increases in MAPK and non-MAPK pathway proteins that may represent targets for future combination regimens. Intrinsic-targeted options have potential to address paucity of medical treatment options for HNSCC cancer patients, enhance response to extrinsic targeted agents, and/or reduce morbidity as neoadjuvant to surgical treatments.

6 October 2020 in Current Treatment Options in Oncology
Verified
Journal Article
Closed access
PDF file
JMJennifer Moy
Jennifer Moy
RLRyan Li
Ryan Li